Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 4/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22276504 | 1.00 | HTR1B (0.39) | HTR1BHTR1DMEN1KMT2APRMT3 | |
| SCHEMBL1254865 | 1.00 | HTR1B (0.39) | HTR1BHTR1DMEN1KMT2APRMT3 | |
| SCHEMBL22276507 | 1.00 | HTR1B (0.39) | HTR1BHTR1DMEN1KMT2APRMT3 | |
| SCHEMBL8403572 | 1.00 | HTR1B (0.39) | HTR1BHTR1DMEN1KMT2APRMT3 | |
| SCHEMBL301651 | 0.96 | — | — | |
| SCHEMBL24774285 | 0.88 | EPHX1 (0.38) | HTR1BHTR1DMEN1KMT2AEPHX1 | |
| SCHEMBL21876827 | 0.88 | KDM4E (0.37) | HTR1BHTR1DMEN1KMT2A | |
| SCHEMBL21455985 | 0.88 | HTR1D (0.33) | HTR1BHTR1DMEN1KMT2A | |
| SCHEMBL22269102 | 0.88 | ALDH1A1 (0.39) | HTR1BHTR1DMEN1KMT2AEPHX1 | |
| SCHEMBL24378505 | 0.88 | ALDH1A1 (0.39) | HTR1BHTR1DMEN1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | HTR1B 2079/4885HTR1D 2270/4885MEN1 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.